modelRanibizumab
Extends from Pharmacolibrary.Drugs.ATC.S.S01LA04.
Information
| name: | Ranibizumab | |
| ATC code: | S01LA04 | route: | intravitreal |
| compartments: | 1 | |
| dosage: | 0.5 | mg |
| volume of distribution: | 2.88 | L |
| clearance: | 0.22 | L/day |
| other parameters in model implementation | ||
Ranibizumab is a recombinant, humanized, monoclonal antibody fragment (Fab) that binds to and inhibits vascular endothelial growth factor A (VEGF-A). It is primarily used for the treatment of neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema, macular edema following retinal vein occlusion, and myopic choroidal neovascularization. Ranibizumab is an approved medication and is widely used in ophthalmology.
Pharmacokinetics
Reported pharmacokinetic parameters in adult patients with neovascular AMD after intravitreal injection of 0.5 mg ranibizumab.
References
Kågedal, M, et al., & Maass, KF (2023). Population Pharmacokinetics of Ranibizumab Delivered via the Port Delivery System Implanted in the Eye in Patients with Neovascular Age-Related Macular Degeneration. Journal of clinical pharmacology 63(11) 1210–1220. DOI:10.1002/jcph.2290 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37291950
Fidler, M, et al., & Fielder, AR (2020). Ranibizumab Population Pharmacokinetics and Free VEGF Pharmacodynamics in Preterm Infants With Retinopathy of Prematurity in the RAINBOW Trial. Translational vision science & technology 9(8) 43–None. DOI:10.1167/tvst.9.8.43 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32855889
Zhang, Y, et al., & Campochiaro, PA (2014). Pharmacokinetics of ranibizumab after intravitreal administration in patients with retinal vein occlusion or diabetic macular edema. Ophthalmology 121(11) 2237–2246. DOI:10.1016/j.ophtha.2014.05.012 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25001159
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)